News

Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in ...
Finanznachrichten3mon
Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions ...
SONNET BIOTHERAPEUTICS HOLDINGS INC WKN: A40NG9ISIN: US83548R4020Ticker-Symbol: H3D0 NASDAQ 18.06.25 | 21:59 1,160 0,00 % 0,000 Branche Nahrungsmittel/Agrar Aktienmarkt Sonstige 1-Jahres-Chart 5 ...
Nasdaq3mon
Sonnet BioTherapeutics Announces Notice of Allowance for Second Patent on Variant Interleukin-18 Binding Protein for Enhanced Cancer Therapeutics - Nasdaq
Sonnet’s variant human IL-18 BPR is a key cytokine which comprises substitutions at the following amino acid positions: Y1, M51, M60, S105 and D110, relative to human wildtype IL-18 ...
Investing3mon
Sonnet BioTherapeutics secures new IL-18 patent
See disclosure here or remove ads. John Cini, Ph.D., Sonnet’s Chief Scientific Officer, commented on the challenges of IL-18 clinical therapies and the potential of IL-18BPR to overcome these by ...
Morningstar3mon
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding ... - Morningstar
Sonnet’s variant human IL-18BPR is a key cytokine which comprises substitutions at the following amino acid positions: Y1, M51, M60, S105 and D110, relative to human wildtype IL-18 ...
Investing3mon
Sonnet BioTherapeutics secures new IL-18 patent - Investing.com
Company News Published 03/19/2025, 08:56 AM 0 Sonnet BioTherapeutics secures new IL-18 patent SONN -3.52% ...
manilatimes3mon
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant ...
PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company” or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic ...
imdb.com5mon
Shakespeare’s Sonnet 18 and an Irish Song Tradition Inspired Paul McCartney on ‘I Saw Her Standing There’ - IMDb
Shakespeare’s Sonnet 18 and an Irish song tradition inspired Paul McCartney on The Beatles‘ “I Saw Her Standing There.” Paul used many of his literary and musical favorites in his songs. The Beatles, ...
Finanznachrichten8mon
Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug ...
Sonnet is developing two novel bifunctional cytokine molecules, IL-18 BPR -F H AB-IL12 and IL-18 BPR -F H AB, both of which contain a unique IL-18 domain that does not bind the inhibitor IL-18BP ...